Secondary changes in the peripheral liver due to kaposiform haemangioendothelioma in the hepatic hilum: a report of two transplant cases.

HistopathologyMar 28, 2026 (epub)

Rishi Agrawal, Owen Lawrence Cain, James Ferguson et al.

✦ AI-curated · Sources linked

Case in brief

Two patients underwent liver transplantation for liver failure associated with clinically unsuspected kaposiform haemangioendothelioma (KHE) at the hepatic hilum. In one, liver failure beginning in childhood had been labelled cryptogenic cirrhosis; the explant showed hilar KHE surrounding portal-vein branches, with peripheral obliterative portal venopathy and nodular regenerative hyperplasia but no cirrhosis. The other had been diagnosed with primary sclerosing cholangitis (PSC) after obstructive liver failure and initial investigations. The explant revealed KHE around the common hepatic duct and peripheral biliary-pattern cirrhosis, supporting secondary sclerosing cholangitis. Transplantation provided the diagnosis in both cases.

What made this case unusual

An unsampled hilar KHE produced distinct secondary changes in the peripheral liver, mimicking cryptogenic cirrhosis in one patient and PSC in the other.

Diagnostic / clinical pearl

When peripheral liver biopsy findings do not fit the clinical history, consider whether an unsampled hilar lesion is causing secondary parenchymal changes.

Source

Published in Histopathology. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.